ANTX
AN2 Therapeutics, Inc.
Key Financials
Operating Income
$-38109000
↑ 32.9%
Net Income
$-35174000
↑ 31.5%
EPS (Diluted)
$-1.16
↑ 32.6%
Total Assets
$62.0M
↓ 32.7%
Total Liabilities
$8.9M
↓ 13.2%
Shareholders' Equity
$53.1M
↓ 35.2%
Cash & Equivalents
$19.9M
↓ 6.6%
Operating Cash Flow
$-29834000.00
↑ 39.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/10/2026 | View on SEC |
| 4 | 4/10/2026 | View on SEC |
| 4 | 4/10/2026 | View on SEC |
| S-3 | 4/9/2026 | View on SEC |
| 8-K | 4/9/2026 | View on SEC |
| D | 3/25/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANTX |
| Company Name | AN2 Therapeutics, Inc. |
| CIK | 1880438 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 331-9090 |